▎Armstrong
2024年10月29日，葛兰素史克宣布以3亿美元预付款+5.5亿美元里程碑金额引进恩沐生物的CMG1A46，该分子目前处于血液瘤一期临床，自免适应症预计2025年进入一期临床。
CMG1A46为一款CD3/CD19/CD20三抗，TAA与CD3为2:1价态设计，同时覆盖CD19、CD20两个主要的B细胞靶点。2021年12月，博锐生物引进CMG1A46的大中华区权益。
总结
国产自免TCE双抗/三抗连续完成多项重大授权合作，包括同润生物CD3/CD19双抗授权给默沙东，嘉和生物CD3/CD20双抗、岸迈生物BCMA/CD双抗通过NewCo模式出海，恩沐生物CD3/CD19/CD20三抗授权给葛兰素史克等。
（转自：Armstrong生物药资讯）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.